Avantor, Inc. (NYSE:AVTR) Short Interest Update

Avantor, Inc. (NYSE:AVTR) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 33,090,000 shares, a drop of 7.9% from the September 30th total of 35,910,000 shares. Based on an average daily volume of 7,300,000 shares, the short-interest ratio is presently 4.5 days.

Avantor Price Performance

Avantor stock traded down $0.11 during mid-day trading on Friday, hitting $22.26. The stock had a trading volume of 2,961,538 shares, compared to its average volume of 6,425,356. The company has a current ratio of 1.54, a quick ratio of 1.05 and a debt-to-equity ratio of 0.84. The firm’s 50 day moving average is $25.26 and its 200 day moving average is $24.19. The firm has a market capitalization of $15.15 billion, a P/E ratio of 48.63, a P/E/G ratio of 2.71 and a beta of 1.33. Avantor has a one year low of $17.46 and a one year high of $28.00.

Insiders Place Their Bets

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Avantor

A number of hedge funds have recently made changes to their positions in AVTR. Jennison Associates LLC lifted its stake in Avantor by 113.0% in the 1st quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock worth $63,857,000 after purchasing an additional 1,325,026 shares in the last quarter. Swedbank AB bought a new position in Avantor during the first quarter valued at approximately $2,707,000. Diversify Advisory Services LLC purchased a new position in Avantor during the 1st quarter valued at approximately $908,000. BNP Paribas Financial Markets increased its stake in Avantor by 42.4% in the 1st quarter. BNP Paribas Financial Markets now owns 309,394 shares of the company’s stock worth $7,911,000 after acquiring an additional 92,098 shares during the last quarter. Finally, William Blair Investment Management LLC raised its holdings in shares of Avantor by 44.6% during the 1st quarter. William Blair Investment Management LLC now owns 1,047,732 shares of the company’s stock worth $26,791,000 after acquiring an additional 322,985 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AVTR has been the topic of several research analyst reports. Robert W. Baird lowered their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday. Barclays dropped their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Morgan Stanley boosted their price target on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Stifel Nicolaus raised their price objective on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 target price on shares of Avantor in a report on Thursday, September 26th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Avantor has an average rating of “Moderate Buy” and an average price target of $27.57.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.